Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Capital Expenditures: 2015-2024

Historic Capital Expenditures for Axsome Therapeutics (AXSM) over the last 10 years, with Dec 2024 value amounting to $270,000.

  • Axsome Therapeutics' Capital Expenditures fell 35.56% to $58,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $439,000, marking a year-over-year increase of 77.73%. This contributed to the annual value of $270,000 for FY2024, which is 53.61% down from last year.
  • According to the latest figures from FY2024, Axsome Therapeutics' Capital Expenditures is $270,000, which was down 53.61% from $582,000 recorded in FY2023.
  • Axsome Therapeutics' Capital Expenditures' 5-year high stood at $702,000 during FY2022, with a 5-year trough of $45,891 in FY2020.
  • Moreover, its 3-year median value for Capital Expenditures was $582,000 (2023), whereas its average is $518,000.
  • As far as peak fluctuations go, Axsome Therapeutics' Capital Expenditures surged by 571.16% in 2021, and later slumped by 53.61% in 2024.
  • Axsome Therapeutics' Capital Expenditures (Yearly) stood at $45,891 in 2020, then spiked by 571.16% to $308,000 in 2021, then soared by 127.92% to $702,000 in 2022, then fell by 17.09% to $582,000 in 2023, then slumped by 53.61% to $270,000 in 2024.